Wall Street analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will post $2.10 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Crispr Therapeutics’ earnings. The lowest sales estimate is $500,000.00 and the highest is $3.70 million. Crispr Therapeutics posted sales of $2.34 million during the same quarter last year, which suggests a negative year over year growth rate of 10.3%. The company is scheduled to report its next quarterly earnings report on Friday, March 9th.
According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $2.10 million for the current financial year, with estimates ranging from $9.20 million to $12.70 million. For the next financial year, analysts forecast that the business will report sales of $14.67 million per share, with estimates ranging from $2.00 million to $24.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Crispr Therapeutics.
Several brokerages have issued reports on CRSP. Zacks Investment Research lowered shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. BidaskClub upgraded shares of Crispr Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 25th. SunTrust Banks upgraded shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. Piper Jaffray Companies reiterated a “buy” rating and set a $22.75 target price (down from $39.00) on shares of Crispr Therapeutics in a research report on Wednesday, January 10th. Finally, Oppenheimer began coverage on shares of Crispr Therapeutics in a research report on Thursday, December 7th. They set a “hold” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $22.81.
Shares of Crispr Therapeutics (NASDAQ CRSP) traded down $0.45 during trading on Friday, reaching $41.16. 1,559,569 shares of the company’s stock traded hands, compared to its average volume of 1,065,162. Crispr Therapeutics has a twelve month low of $13.50 and a twelve month high of $45.00. The company has a market capitalization of $1,890.00 and a price-to-earnings ratio of -128.63.
In other news, major shareholder Corp /De/ Celgene sold 1,112,446 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $18.98, for a total value of $21,114,225.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thomas Woiwode sold 1,700 shares of the business’s stock in a transaction that occurred on Friday, November 24th. The stock was sold at an average price of $20.21, for a total transaction of $34,357.00. Following the completion of the sale, the director now owns 8,218 shares of the company’s stock, valued at $166,085.78. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,559,450 shares of company stock valued at $31,533,688. Company insiders own 39.98% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in CRSP. Wells Fargo & Company MN lifted its holdings in shares of Crispr Therapeutics by 459.7% in the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after acquiring an additional 6,560 shares during the last quarter. Vanguard Group Inc. bought a new stake in shares of Crispr Therapeutics in the 2nd quarter worth approximately $273,000. Ark Investment Management LLC bought a new stake in shares of Crispr Therapeutics in the 2nd quarter worth approximately $206,000. Moloney Securities Asset Management LLC bought a new stake in shares of Crispr Therapeutics in the 3rd quarter worth approximately $235,000. Finally, Hershey Trust Co. bought a new stake in shares of Crispr Therapeutics in the 3rd quarter worth approximately $768,000. Hedge funds and other institutional investors own 24.55% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/02/21/crispr-therapeutics-ag-crsp-expected-to-post-quarterly-sales-of-2-10-million.html.
Crispr Therapeutics Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.